Prempro Related Published Studies
Well-designed clinical trials related to Prempro (Conjugated Estrogens / Medroxyprogesterone)
Effects of alcohol and cigarette smoking on change in serum estrone levels in postmenopausal women randomly assigned to fixed doses of conjugated equine estrogens with or without a progestin. [2008.03]
Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. [2007.08]
Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. [2007.05]
Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. [2006.12]
Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. [2006.11]
Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women. [2006.07]
The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. [2006.03]
The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. [2006.03]
Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women. [2006.02.20]
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. [2006.02.13]
Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin. [2006.01.10]
Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women. [2005.10]
[Modification of C3 and C4 levels after the administration of conjugated estrogens plus medroxiprogesterone or raloxifene in postmenopausal women] [2005.10]
Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. [2005.09.16]
Effect on sexual life--a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate. [2005.04]
Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. [2005.04]
The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). [2004.11.15]
Effect of continuous administration of conjugated estrogen plus medroxyprogesterone acetate (Premelle) in postmenopausal women in Taiwan. [2004.07]
Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. [2004.07]
Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. [2004.06.23]
Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins. [2004.06.15]
Lipoprotein compositional changes with combination hormone therapy (conjugated estrogen and medroxyprogesterone) in African American women. [2004.05]
Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. [2004.05]
Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. [2003.11]
A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin. [2003.04]
Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. [2003.01]
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. [2002.09.03]
Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. [2002.05.22]
[Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis] [2002.05]
A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. [2002.03]
Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. [2001.11]
Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. [2001.09]
Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. [2001.07]
Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. [2001.07]
Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. [2001.06]
Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. [2001.06]
Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate. [2001.05]
Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. [2001.04.17]
Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. [2001]
[Comparative study between estradiol valerate combined with cyproterone acetate, and conjugated equine estrogens combined with medroxyprogesterone acetate as hormone replacement therapy in climacteric] [2000.11]
The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. [2000.07.31]
Dose response effect of conjugated equine oestrogen on blood pressure in postmenopausal women with hypertension. [2000]
Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate). [1999.05.31]
Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women. [1999.05]
A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. [1998.09]
Effects of adding C-19 versus C-21 progestin to conjugated estrogen in moderately hypercholesterolemic postmenopausal women. [1998.04]
Hormonal treatment and psychological function during the menopausal transition: an evaluation of the effects of conjugated estrogens/cyclic medroxyprogesterone acetate. [1998.03]
A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. [1996.07]
The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. [1996.04]
Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate. [1995.04]
Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. [1994.12]
Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. [1994.05]
Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. [1994.05]
Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin. [1994.02]
A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. [1993.07]
Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. [1993.07]
Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. [1991.04]
Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I. [1991.02]
Well-designed clinical trials possibly related to Prempro (Conjugated Estrogens / Medroxyprogesterone)
Estrogen plus progestin and risk of benign proliferative breast disease. [2008.09]
Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. [2008.09]
Health related quality of life after combined hormone replacement therapy: randomised controlled trial. [2008.08.21]
Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial. [2008.08.01]
A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women's Health Initiative Memory Study. [2008.08]
Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux. [2008.07]
Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. [2008.06.01]
Kidney dysfunction and sudden cardiac death among women with coronary heart disease. [2008.06]
Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. [2008.05.23]
Hormone replacement therapy and stroke. [2008.04]
Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. [2008.04]
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. [2008.03.05]
B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram. [2008.03]
Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. [2008.02.25]
Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women. [2008.02]
The Women's Health Initiative: Lessons Learned. [2008]
Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. [2007.09.25]
Can Biomarkers Identify Women at Increased Stroke Risk? The Women's Health Initiative Hormone Trials. [2007.06.15]
Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. [2007.06.15]
Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study. [2007.06]
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. [2007.04.04]
Endometrial effects of tibolone. [2007.03]
Efficacy of citalopram on climacteric symptoms. [2007.03]
Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. [2007.03]
Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity. [2007.02]
An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment. [2007.01]
Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. [2007.01]
Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. [2006.12.19]
Impact of Cyclooxygenase Inhibitors in the Women's Health Initiative Hormone Trials: Secondary Analysis of a Randomized Trial. [2006.09.29]
Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. [2006.09.20]
Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. [2006.09]
A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings. [2006.09]
Role of ovarian hormones in the regulation of protein metabolism in women: effects of menopausal status and hormone replacement therapy. [2006.09]
Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT. [2006.08.20]
Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy. [2006.08.14]
Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial. [2006.08]
Menopausal hormone therapy in a health maintenance organization before and after women's health initiative hormone trials termination. [2006.05]
Effects of combination estrogen plus progestin hormone treatment on cognition and affect. [2006.05]
The effect of low dose hormone therapy on mammographic breast density. [2006.04.20]
Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. [2006.04.01]
[Profiles of irregular bleeding induced by low-dose hormone therapy and Chinese formulated herbs products] [2006.04]
The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. [2006.04]
Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. [2006.03.20]
|
